- $892.12m
- $804.35m
- $348.88m
- 87
- 52
- 42
- 63
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 24.93 | ||
| PEG Ratio (f) | 1.77 | ||
| EPS Growth (f) | 16.37% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.14 | ||
| Price to Tang. Book | 6.04 | ||
| Price to Free Cashflow | 16.13 | ||
| Price to Sales | 2.96 | ||
| EV to EBITDA | 15.28 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 23.67% | ||
| Return on Equity | 22.29% | ||
| Operating Margin | 15.3% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 248.23 | 258.62 | 267.84 | 321.48 | 348.88 | 374.72 | 417.54 | 3.12% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | -46.36 | +1.99 | +39.84 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
MiMedx Group, Inc. is a placental biologics company focused on providing a portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. Its product portfolio categories include Wound Care and Surgical. The Wound Care products include EPIFIX and EPIEFFECT, which are marketed for external use, such as in advanced wound care applications. Its EPICORD, EPICORD Expandable and EPIEFFECT product lines also offer an alternative treatment option to address larger, deeper wounds. Its Surgical and Other product offering includes AMNIOFIX and AMNIOEFFECT, which are used in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. It also offers HELIOGEN, an advanced bovine collagen matrix containing type I and type III collagen that is intended for the management of moderately to heavily exudating wounds and to control minor bleeding.
Directors
- M. Kathleen Behrens Wilsey NEC (68)
- Timothy Wright CEO (63)
- Peter Carlson CFO (56)
- Rohit Kashyap EVP (49)
- Robert Stein EVP (70)
- Mark Graves SVP (56)
- Jack Howarth SVP
- Scott Turner SVP (55)
- William Hulse GCN (47)
- Phyllis Gardner DRC (70)
- James Bierman IND (68)
- Michael Giuliani IND (66)
- William Hawkins IND (67)
- Cato Laurencin IND (62)
- K. Todd Newton IND (58)
- Martin Sutter IND (66)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- February 28th, 2008
- Public Since
- August 20th, 2007
- No. of Shareholders
- 770
- No. of Employees
- 837
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 147,702,140
- Address
- 1775 W Oak Commons Court, Ne, MARIETTA, 30062
- Web
- https://mimedx.com/
- Phone
- +1 7706519100
- Contact
- Matt Notarianni
- Auditors
- Deloitte & Touche LLP
Latest News for MDXG
Upcoming Events for MDXG
MiMedx Group Inc Annual Shareholders Meeting
MiMedx Group Inc Annual Shareholders Meeting
Q2 2025 MiMedx Group Inc Earnings Release
Q3 2025 MiMedx Group Inc Earnings Release
Similar to MDXG
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
Acurx Pharmaceuticals
NASDAQ Capital Market
FAQ
As of Today at 22:03 UTC, shares in MiMedx are trading at $7.05. This share price information is delayed by 15 minutes.
Shares in MiMedx last closed at $7.05 and the price had moved by -10.65% over the past 365 days. In terms of relative price strength the MiMedx share price has underperformed the S&P500 Index by -20.47% over the past year.
The overall consensus recommendation for MiMedx is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreMiMedx does not currently pay a dividend.
MiMedx does not currently pay a dividend.
MiMedx does not currently pay a dividend.
To buy shares in MiMedx you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $7.05, shares in MiMedx had a market capitalisation of $1.04bn.
Here are the trading details for MiMedx:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: MDXG
Based on an overall assessment of its quality, value and momentum MiMedx is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in MiMedx is $12.00. That is 70.21% above the last closing price of $7.05.
Analysts covering MiMedx currently have a consensus Earnings Per Share (EPS) forecast of $0.25 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like MiMedx. Over the past six months, its share price has underperformed the S&P500 Index by -24.86%.
As of the last closing price of $7.05, shares in MiMedx were trading -6.06% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The MiMedx PE ratio based on its reported earnings over the past 12 months is 24.93. The shares last closed at $7.05.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
MiMedx's management team is headed by:
- M. Kathleen Behrens Wilsey - NEC
- Timothy Wright - CEO
- Peter Carlson - CFO
- Rohit Kashyap - EVP
- Robert Stein - EVP
- Mark Graves - SVP
- Jack Howarth - SVP
- Scott Turner - SVP
- William Hulse - GCN
- Phyllis Gardner - DRC
- James Bierman - IND
- Michael Giuliani - IND
- William Hawkins - IND
- Cato Laurencin - IND
- K. Todd Newton - IND
- Martin Sutter - IND